NASD · Healthcare · Medical Devices · USA
Delcath Systems Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.
Delcath Systems is an interventional oncology company that develops treatments for cancers primary or metastatic to the liver. The company's lead product, HEPZATO KIT, a drug-device combination approved by the FDA, treats uveal melanoma with unresectable hepatic metastases. In Europe, Delcath markets CHEMOSAT, a hepatic delivery system for melphalan, at major medical centers for various liver cancers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Delcath Systems Inc stock.
Overvalued: intrinsic value $5.21 per share, market price $19.37, margin of safety -271.7% (as of 2026-11-17).
Discounting its cash flows at 8.2% values the shares at $5.21; the price of $19.37 is 272% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 140 Medical Devices stocks
46 more in this industry show a wider margin of safety.
DCTH is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 8.2% values the shares at $5.21; the price of $19.37 is 272% above that value.
$5.21 per share (as of the 2026-11-17 close), against a market price of $19.37. That is a margin of safety of -271.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.